Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
6.64
+0.18 (2.79%)
At close: May 28, 2026, 4:00 PM EDT
6.60
-0.04 (-0.60%)
After-hours: May 28, 2026, 6:41 PM EDT
Vanda Pharmaceuticals Employees
Vanda Pharmaceuticals had 533 employees as of December 31, 2025. The number of employees increased by 165 or 44.84% compared to the previous year.
Employees
533
Change (1Y)
165
Growth (1Y)
44.84%
Revenue / Employee
$408,597
Profits / Employee
-$449,432
Market Cap
399.30M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 533 | 165 | 44.84% |
| Dec 31, 2024 | 368 | 165 | 81.28% |
| Dec 31, 2023 | 203 | -87 | -30.00% |
| Dec 31, 2022 | 290 | 12 | 4.32% |
| Dec 31, 2021 | 278 | -14 | -4.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| Puma Biotechnology | 179 |
| Lyell Immunopharma | 161 |
| Artiva Biotherapeutics | 104 |
| Verastem | 102 |
| OmniAb | 89 |
| Larimar Therapeutics | 71 |
| Atea Pharmaceuticals | 55 |
VNDA News
- 1 day ago - Vanda Pharmaceuticals’ imsidolimab granted orphan drug designation in Japan - TheFly
- 1 day ago - Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis - PRNewsWire
- 9 days ago - Vanda Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 10 days ago - Vanda Pharmaceuticals Slides: Corporate presentation - Filings
- 17 days ago - Vanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright - TheFly
- 21 days ago - Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences - PRNewsWire
- 21 days ago - Vanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year - TheFly
- 21 days ago - Vanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M - TheFly